logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO-GI 2019—Pembrolizumab shows OS advantage in PD-L1 esophageal cancer

KEYNOTE-181 data support 2L pembrolizumab over chemotherapy in advanced disease.